Charlotte M. Proby

Charlotte M. Proby

Auto-generated profile, based on publicly available information

Charlotte M. Proby

Division of Cancer Research, School of Medicine University of Dundee Dundee UK

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Gareth InmanGareth Inman
Gareth Inman
JWJun Wang
Jun Wang
ANAi Nagano
Ai Nagano
LALudmil B. Alexandrov
Ludmil B. Alexandrov
KPKarin J. Purdie
Karin J. Purdie
ILIrene M. Leigh
Irene M. Leigh
Cutaneous squamous cell carcinoma (cSCC) has a high tumour mutational burden (50 mutations per megabase DNA pair). Here, we combine whole-exome analyses from 40 primary cSCC tumours, comprising 20 well-differentiated and 20 moderately/poorly differentiated tumours, with accompanying clinical data from a longitudinal study of immunosuppressed and immunocompetent patients and integrate this analysis with independent gene expression studies. We identify commonly mutated genes, copy number changes and altered pathways and processes. Comparisons with tumour differentiation status suggest events which may drive disease progression. Mutational signature analysis reveals the presence of a novel signature (signature 32), whose incidence correlates with chronic exposure to the immunosuppressive drug azathioprine. Characterisation of a panel of 15 cSCC tumour-derived cell lines reveals that they accurately reflect the mutational signatures and genomic alterations of primary tumours and provide a valuable resource for the validation of tumour drivers and therapeutic targets.

1 March 2019 in JAMA Dermatology
Verified
Journal Article
Open access
PDF file
ZVZoë C. Venables
Zoë C. Venables
PAPhilippe Autier
Philippe Autier
TNTamar Nijsten
Tamar Nijsten
KWKwok F. Wong
Kwok F. Wong
SLSinéad M. Langan
Sinéad M. Langan
ILIrene M. Leigh
Irene M. Leigh
Importance Cutaneous squamous cell carcinoma (cSCC) is the most common skin cancer with metastatic potential, but epidemiologic data are poor. Changes to the National Cancer Registration and Analysis Service (NCRAS) in England have allowed more accurate data analysis of primary and metastatic cSCC since 2013. Objective To assess the national incidence of cSCC and metastatic cSCC (mcSCC) in England from 2013 through 2015. Design, Setting, and Participants This national population-based study identified a cohort of patients with cSCC and mcSCC in England from January 1, 2013, through December 31, 2015. Patients were identified using diagnostic codes derived from pathology reports in the NCRAS. Data were analyzed from March 1, 2017, through March 1, 2018. Main Outcomes and Measures Incidence rates across sex and risk factors for cSCC were derived from the NCRAS data. Risk of occurrence of mcSCC among the population with cSCC was assessed with Cox proportional hazards regression analysis to determine indicators of mcSCC. Results Among the 76 977 patients with first primary cSCC in 2013 through 2015 (62.7% male; median age, 80 years [interquartile range, 72-86 years]), the age-standardized rates for the first registered cSCC in England from 2013 through 2015 were 77.3 per 100 000 person-years (PY) (95% CI, 76.6-78.0) in male patients and 34.1 per 100 000 PY (95% CI, 33.7-34.5) in female patients. Increased primary cSCC tumor count was observed in older, white male patients in lower deprivation quintiles. After a maximum follow-up of 36 months, cumulative incidence of mcSCC developed in 1.1% of women and 2.4% of men with a primary cSCC. Significant increases in the risk of metastasis with adjusted hazard rates of approximately 2.00 were observed in patients who were aged 80 to 89 years (hazard ratio [HR], 1.23; 95% CI, 1.07-1.43), 90 years or older (HR, 1.35; 95% CI, 1.09-1.66), male (HR, 1.79; 95% CI, 1.52-2.10), immunosuppressed (HR, 1.99; 95% CI, 1.64-2.42), and in higher deprivation quintiles (HR for highest quintile, 1.64; 95% CI, 1.35-2.00). Primary cSCC located on the ear (HR, 1.70; 95% CI, 1.42-2.03) and lip (HR, 1.85; 95% CI, 1.29-2.63) were at highest risk of metastasis. Conclusions and Relevance This study presents the first national study of the incidence of mcSCC. With limited health care resources and an aging population, accurate epidemiologic data are essential for informing future health care planning, identifying high-risk patients, and evaluating skin cancer prevention policies.

12 March 2019 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
ZVZ.C. Venables
Z.C. Venables
TNT. Nijsten
T. Nijsten
KWK.F. Wong
K.F. Wong
PAP. Autier
P. Autier
JBJ. Broggio
J. Broggio
ILI.M. Leigh
I.M. Leigh
Background Basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), together known as keratinocyte cancers (KCs), are the commonest cancer in Caucasian populations. Recent improvements to registry data collection in England has allowed more accurate analysis of the epidemiology of BCC and cSCC and for the first time we are able to provide an accurate (representative) tumour burden for KC in the UK. Objective To estimate the incidence of BCC and cSCC in the UK. Methods A cohort of patients with KCs between 2013 and 2015 were identified using linkage to diagnostic codes derived from pathology reports collected into the national cancer registry. Data from England's cancer registry were combined with data from Scotland, Northern Ireland and Wales. European Age Standardised incidence rates (EASRs) of the first BCC and cSCC per patient per annum (PPPA) were calculated. Results In the UK, the EASR of the first BCC and cSCC PPPA 2013‐2015 were 285 and 77 per 100,000 person‐years respectively (211,120 KCs total in 2015). The mean annual percentage increase was 5% between 2013‐2015 for both BCC and cSCC. By counting the first tumour per patient per year, we include an additional 51% KCs compared to the previous reporting technique which counts only the first BCC and cSCC in a patient's lifetime, yet it represents a probable underestimation of 5‐11% of the true tumour count. Conclusions Based on an improved methodology, a more representative incidence of KC is presented, which is essential to healthcare planning and will lead to improved understanding of the epidemiology of KC.

15 April 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
PNPriyadharsini Nagarajan
Priyadharsini Nagarajan
MAMaryam M. Asgari
Maryam M. Asgari
AGAdele C. Green
Adele C. Green
SGSamantha M. Guhan
Samantha M. Guhan
SASarah T. Arron
Sarah T. Arron
ATAmanda Toland
Amanda Toland
Cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC) are keratinocyte carcinomas, the most frequently diagnosed cancers in fair-skinned populations. Ultraviolet radiation (UVR) is the main driving carcinogen for these tumors, but immunosuppression, pigmentary factors, and aging are also risk factors. Scientific discoveries have improved the understanding of the role of human papillomaviruses (HPV) in cSCC as well as the skin microbiome and a compromised immune system in the development of both cSCC and BCC. Genomic analyses have uncovered genetic risk variants, high-risk susceptibility genes, and somatic events that underlie common pathways important in keratinocyte carcinoma tumorigenesis and tumor characteristics that have enabled development of prediction models for early identification of high-risk individuals. Advances in chemoprevention in high-risk individuals and progress in targeted and immune-based treatment approaches have the potential to decrease the morbidity and mortality associated with these tumors. As the incidence and prevalence of keratinocyte carcinoma continue to increase, strategies for prevention, including effective sun-protective behavior, educational interventions, and reduction of tanning bed access and usage, are essential. Gaps in our knowledge requiring additional research to reduce the high morbidity and costs associated with keratinocyte carcinoma include better understanding of factors leading to more aggressive tumors, the roles of microbiome and HPV infection, prediction of response to therapies including immune checkpoint blockade, and how to tailor both prevention and treatment to individual risk factors and needs.

30 June 2011 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
CPC. M. Proby
C. M. Proby
CHC. A. Harwood
C. A. Harwood
RNRachel Neale
Rachel Neale
AGA. C. Green
A. C. Green
SES. Euvrard
S. Euvrard
TGthe EPI‐HPV‐UV‐CA group
the EPI‐HPV‐UV‐CA group
We examined the association between betapapillomavirus (betaPV) infection and cutaneous squamous cell carcinoma (SCC) in organ transplant recipients. A total of 210 organ transplant recipients with previous SCC and 394 controls without skin cancer were included. The presence of 25 betaPV types in plucked eyebrow hairs was determined using a human papillomavirus (HPV) DNA genotyping assay, and antibodies for the 15 most prevalent betaPV types were detected using multiplex serology. We used multivariate logistic regression models to estimate associations between various measures of betaPV infection and SCC. BetaPV DNA was highly prevalent (>94%) with multiple types frequently detected in both groups. We found a significant association between SCC and the concordant detection of both antibodies and DNA for at least one betaPV type (adjusted OR 1.6; 95% CI 1.1;2.5). A borderline‐significant association with SCC was found for HPV36 (adjusted OR 2.4; CI 1.0;5.4), with similar associations for HPV5, HPV9 and HPV24. These data provide further evidence of an association between betaPV infection and SCC in organ transplant recipients. Confirmation of a betaPV profile predictive of risk for SCC may pave the way for clinically relevant pretransplant HPV screening and the development of preventive and therapeutic HPV vaccination.

4 November 2020 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
SKS.G. Keohane
S.G. Keohane
JBJ. Botting
J. Botting
PBP.G. Budny
P.G. Budny
ODO.M. Dolan
O.M. Dolan
KFK. Fife
K. Fife
TUthe British Association of Dermatologists’ Clinical Standards Unit
the British Association of Dermatologists’ Clinical Standards Unit
The overall objective of the guideline is to provide up‐to‐date, evidence‐based recommendations for the management of cutaneous squamous cell carcinoma (cSCC). The document aims to: offer an appraisal of all relevant literature up to 30th January 2020, focusing on any key developments address important, practical clinical questions relating to the primary guideline objective. provide guideline recommendations and if appropriate research recommendations